ATLANTA, GA – – (Businesswire – February 7, 2019) – – Holzer & Holzer, LLC is investigating whether certain statements made by Solid Biosciences, Inc. (“Solid Biosciences” or the “Company”) (NASDAQ: SLDB) complied with federal securities laws. On February 7, 2019, the price of Solid Biosciences shares fell significantly following the Company’s announcement of preliminary findings from IGNITE DMD, the Company’s Phase I/II dose-ascending clinical trial evaluating the safety and efficacy of SGT-001 microdystrophin gene transfer for the treatment of Duchenne muscular dystrophy (DMD). If you purchased Solid Biosciences shares and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Marshall P. Dees, Esq. at firstname.lastname@example.org, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.